Collet-Sicard syndrome as an initial presentation of prostate cancer: a case report
© Villatoro et al; licensee BioMed Central Ltd. 2011
Received: 7 October 2010
Accepted: 14 July 2011
Published: 14 July 2011
Collet-Sicard syndrome is caused by lesions at the base of the skull affecting the lower cranial nerves. It is associated with various etiologies of tumoral and other origin. Although this syndrome has been reported previously in the literature, most cases are diagnosed as part of primary disease follow-up. This case is unusual because of the diagnosis of bone metastasis secondary to prostate cancer.
We present the case of a 70-year-old Caucasian man with a three-week history of headache and maxillary pain on the right side together with paresis of the low cranial nerves. This study was carried out with a computed tomography (CT) scan of the larynx and neck and MRI, which revealed a bone lesion at the base of the skull affecting the right occipital condyle and part of the right side of the basilar bone. On the basis of differential diagnosis, a fibrous dysplasia, Paget's disease or metastasis was considered. Finally, and after other studies were performed, a diagnosis of bone metastasis secondary to prostate cancer was established.
We think that this case is curious because it involved an initial presentation of metastatic prostate cancer. It is important this should be considered in the differential diagnosis when a patient with unusual clinical findings is first seen in view of the fact that first-line hormonal treatment may control the disease for months or years.
Collet-Sicard syndrome is caused by lesions at the base of the skull affecting the lower cranial nerves, which produces dysphonia, displacement of the palate, and atony of the trapezius muscle and sternocleidomastoid, as well as anesthesia of the larynx, pharynx and soft palate. It is associated with various etiologies of tumoral and other origins. The differential diagnosis is important. Among the non-tumoral factors causing Collet-Sicard syndrome, the most common are traumatic events (fractures at the base of the skull, aneurisms, and so on), inflammatory processes (osteomyelitis, Paget's disease, and so on) or other alterations such as diabetes mellitus or porphyrias . However, considering a potential tumor cause in the differential diagnosis is important.
Collet-Sicard syndrome may be diagnosed based on clinical history, a physical examination or imaging studies such as computed tomography (CT) and MRI scans . The site most frequently affected is the petrous apex, although the external auditory canal, the middle ear and the mastoid apophysis can also be involved . The symptoms vary depending on the location of occurrence, producing effects ranging from loss of hearing to tinnitus or disorders of cranial nerve VIII, the jugular foramen or the anterior condylar canal. The latter is the site described in our patient's case .
Subsequently, an additional radiographic examination of the lumbar column and pelvis was carried out; this examination did not reveal any lesions suggestive of Paget's disease. A bone gammagraphy was then requested, and images showed multiple pathological foci of tracer uptake in the right maxilla, the rib cage, right scapula, spine and pelvis. These foci were compatible with disseminated bone metastases. The blood analysis was repeated, and tumor markers were studied. The initial prostate-specific antigen (PSA) value was 21.30 ng/mL.
A physical examination revealed an enlarged prostate with a hard consistency, destructured in the left lobe. Because there was a strong suspicion of prostate neoplasm, a biopsy was performed. The anatomic pathology findings were bilateral common adenocarcinoma, with a Gleason grade of 8 (4+4), affecting 60% of the tissue. There was no presence in the periprostatic adipose tissue and no perineural infiltration.
Following the diagnosis of stage IV prostate adenocarcinoma by metastatic bone dissemination with Collet-Sicard or jugular foramen syndrome, hormone treatment was begun with an antiandrogen. Then, 15 days later, a luteinizing hormone-releasing hormone (LHRH) analog was added and a monthly dose of zoledronic acid was subsequently included. The PSA value during the diagnostic process, prior to the start of antiandrogen therapy, was 71.9 ng/mL.
After three months of treatment, our patient was able to swallow normally, but the dysphonia remained. The rightward displacement of the palate, the lowering of the right shoulder and the atony of the right side of the tongue (paresis of cranial nerves XI and XII) remained unaltered. The latest PSA value was 0.11 ng/mL.
The clinical presentation of metastasis to the temporal bone is uncommon, and few cases have been reported. Nevertheless, its incidence is probably greater than commonly estimated because of the number of cases that remain undiagnosed. The multi-symptom nature of metastatic bone disease tends to produce more incapacitating symptoms than those associated with diseases of the temporal bone.
Various retrospective series of patients presenting with this syndrome have been reported in the literature. Vázquez et al. described 21 cases, of which 71% were secondary to neoplasia (57% from paraganglioma and 14% by the direct extension of carcinoma of the cavum) . Imamura et al. reviewed the potential mechanisms responsible for metastatic dissemination to the temporal bone. Of the six patients studied, three cases presented hematogenous dissemination (hepatocellular carcinoma, non-microcytic lung cancer and adenocarcinoma of unknown origin), two cases were the consequence of direct invasion by carcinoma of the head and neck, and one case was caused by leptomeningeal carcinomatosis (carcinoma of transitional cell carcinoma of the renal pelvis) . Gloria-Cruz et al. selected 212 corpses of patients with non-disseminated neoplasias for an autopsical study of the temporal bone. These authors identified 47 patients with metastasis in the temporal bone, and the involvement was bilateral in 62% of these cases. The most frequently occurring site was the petrous apex, and the hematogenous pathway was the normal route of dissemination [5, 6].
The management of Collet-Sicard syndrome consists of treating the cause that originates. In this case, therapy over primary tumor, followed by other measures such as the use of steroids or radiotherapy to help reduce edema and, thus, alleviate symptoms that can be limiting for the patient .
The medical literature contains various descriptions of patients with disseminated prostate cancer who presented with Collet-Sicard syndrome; however, in almost every case, this diagnosis was already known when neurological symptoms began [7–12]. Apart from our patient, only one other case has been reported where metastasis to the temporal bone was the first recognized symptom of the disease . It is important to consider the possibility of the existence of prostate cancer when a patient with an unusual clinical presentation is first seen, in view of the fact that first-line hormonal treatment may control the disease for months or years.
Written informed consent was obtained from the patient for publication of this case report and any accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
- Vázquez BV, Saynes MFJ, Hernández VG: Sindrome de Agujero Rasgado posterior. Casuística y manejo. An Orl Mex. 2002, 47: 4-8.Google Scholar
- Belal A: Metastatic tumours of the temporal bone. A histopathological report. J Laryngol Otol. 1985, 99: 839-846.View ArticlePubMedGoogle Scholar
- Syms MJ, Singson MT, Burgess LP: Evaluation of lower cranial nerve deficits. Otolaryngol Clin North Am. 1997, 30: 489-463.Google Scholar
- Imamura S, Murakami Y: Secondary malignant tumor of the temporal bone. A histopathologic study and review of the world literature. Nippon Jibiinkoka Gakkai Kaiho. 1991, 94: 924-937. 10.3950/jibiinkoka.94.924.View ArticlePubMedGoogle Scholar
- Gloria-Cruz TI, Schachern PA, Paparella MM, Adams GL, Fulton SE: Metastases to temporal bones from primary nonsystemic malignant neoplasms. Arch Otolaryngol Head Neck Surg. 2000, 126: 209-214.View ArticlePubMedGoogle Scholar
- Nelson EG, Hinojosa R: Histopathology of metastatic temporal bone tumors. Arch Otolaryngol Head Neck Surg. 1991, 117: 189-193.View ArticlePubMedGoogle Scholar
- Chacon G, Alexandraki I, Palacio C: Collet-Sicard syndrome: an uncommon manifestation of metastatic prostate cancer. South Med J. 2006, 99: 898-899. 10.1097/01.smj.0000224747.50060.26.View ArticlePubMedGoogle Scholar
- Shine NP, O'Sullivan P: Collet-Sicard syndrome: a rare presentation of metastatic prostate adenocarcinoma. Auris Naus Larynx. 2005, 32: 315-318. 10.1016/j.anl.2005.03.008.View ArticleGoogle Scholar
- Prashant R, Franks A: Collet-Sicard syndrome--a report and review. Lancet Oncol. 2003, 4: 376-377. 10.1016/S1470-2045(03)01097-0.View ArticlePubMedGoogle Scholar
- Satoh H, Nishiyama T, Horiguchi A, Nakashima J, Saito S, Murai M: A case of Collet-Sicard syndrome caused by skull base metastasis of prostate carcinoma. Nippon Hinyokika Gakkai Zasshi. 2000, 91: 562-564.PubMedGoogle Scholar
- Wilson H, Johnson DH: Jugular foramen syndrome as a complication of metastatic cancer of the prostate. South Med J. 1984, 77: 92-93. 10.1097/00007611-198401000-00029.View ArticlePubMedGoogle Scholar
- Onishi A, Shida K: Case of Collet-Sicard syndrome due to metastasis of prostatic cancer. Naika. 1970, 26: 755-757.PubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.